Circulating prolactin levels and risk of epithelial ovarian cancer

Tess V. Clendenen, Alan A. Arslan, Anna E. Lokshin, Mengling Liu, Eva Lundin, Karen L. Koenig, Franco Berrino, Goran Hallmans, Annika Idahl, Vittorio Krogh, Annekatrin Lukanova, Adele Marrangoni, Paola Muti, Brian M. Nolen, Nina Ohlson, Roy E. Shore, Sabina Sieri, Anne Zeleniuch-Jacquotte

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: Indirect evidence from experimental and epidemiological studies suggests that prolactin may be involved in ovarian cancer development. However, the relationship between circulating prolactin levels and risk of ovarian cancer is unknown. Methods: We conducted a nested case-control study of 230 cases and 432 individually matched controls within three prospective cohorts to evaluate whether pre-diagnostic circulating prolactin is associated with subsequent risk of ovarian cancer. We also assessed whether lifestyle and reproductive factors are associated with circulating prolactin among controls. Results: Prolactin levels were significantly lower among post- versus pre-menopausal women, parous versus nulliparous women, and past versus never users of oral contraceptives in our cross-sectional analysis of controls. In our nested case-control study, we observed a non-significant positive association between circulating prolactin and ovarian cancer risk (ORQ4vsQ1 1.56, 95 % CI 0.94, 2.63, p trend 0.15). Our findings were similar in multivariate-adjusted models and in the subgroup of women who donated blood ≥5 years prior to diagnosis. We observed a significant positive association between prolactin and risk for the subgroup of women with BMI ≥25 kg/m2 (ORQ4vsQ1 3.10, 95 % CI 1.39, 6.90), but not for women with BMI 2 (OR Q4vsQ1 0.81, 95 % CI 0.40, 1.64). Conclusions: Our findings suggest that prolactin may be associated with increased risk of ovarian cancer, particularly in overweight/obese women. Factors associated with reduced risk of ovarian cancer, such as parity and use of oral contraceptives, were associated with lower prolactin levels, which suggests that modulation of prolactin may be a mechanism underlying their association with risk.

Original languageEnglish
Pages (from-to)741-748
Number of pages8
JournalCancer Causes and Control
Volume24
Issue number4
DOIs
Publication statusPublished - Apr 2013

Fingerprint

Prolactin
Ovarian Neoplasms
Oral Contraceptives
Case-Control Studies
Ovarian epithelial cancer
Parity
Life Style
Epidemiologic Studies
Cross-Sectional Studies

Keywords

  • Ovarian cancer
  • Plasma
  • Prolactin
  • Serum

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Clendenen, T. V., Arslan, A. A., Lokshin, A. E., Liu, M., Lundin, E., Koenig, K. L., ... Zeleniuch-Jacquotte, A. (2013). Circulating prolactin levels and risk of epithelial ovarian cancer. Cancer Causes and Control, 24(4), 741-748. https://doi.org/10.1007/s10552-013-0156-6

Circulating prolactin levels and risk of epithelial ovarian cancer. / Clendenen, Tess V.; Arslan, Alan A.; Lokshin, Anna E.; Liu, Mengling; Lundin, Eva; Koenig, Karen L.; Berrino, Franco; Hallmans, Goran; Idahl, Annika; Krogh, Vittorio; Lukanova, Annekatrin; Marrangoni, Adele; Muti, Paola; Nolen, Brian M.; Ohlson, Nina; Shore, Roy E.; Sieri, Sabina; Zeleniuch-Jacquotte, Anne.

In: Cancer Causes and Control, Vol. 24, No. 4, 04.2013, p. 741-748.

Research output: Contribution to journalArticle

Clendenen, TV, Arslan, AA, Lokshin, AE, Liu, M, Lundin, E, Koenig, KL, Berrino, F, Hallmans, G, Idahl, A, Krogh, V, Lukanova, A, Marrangoni, A, Muti, P, Nolen, BM, Ohlson, N, Shore, RE, Sieri, S & Zeleniuch-Jacquotte, A 2013, 'Circulating prolactin levels and risk of epithelial ovarian cancer', Cancer Causes and Control, vol. 24, no. 4, pp. 741-748. https://doi.org/10.1007/s10552-013-0156-6
Clendenen TV, Arslan AA, Lokshin AE, Liu M, Lundin E, Koenig KL et al. Circulating prolactin levels and risk of epithelial ovarian cancer. Cancer Causes and Control. 2013 Apr;24(4):741-748. https://doi.org/10.1007/s10552-013-0156-6
Clendenen, Tess V. ; Arslan, Alan A. ; Lokshin, Anna E. ; Liu, Mengling ; Lundin, Eva ; Koenig, Karen L. ; Berrino, Franco ; Hallmans, Goran ; Idahl, Annika ; Krogh, Vittorio ; Lukanova, Annekatrin ; Marrangoni, Adele ; Muti, Paola ; Nolen, Brian M. ; Ohlson, Nina ; Shore, Roy E. ; Sieri, Sabina ; Zeleniuch-Jacquotte, Anne. / Circulating prolactin levels and risk of epithelial ovarian cancer. In: Cancer Causes and Control. 2013 ; Vol. 24, No. 4. pp. 741-748.
@article{06e80db4c8b7415d88d389757da0cffa,
title = "Circulating prolactin levels and risk of epithelial ovarian cancer",
abstract = "Purpose: Indirect evidence from experimental and epidemiological studies suggests that prolactin may be involved in ovarian cancer development. However, the relationship between circulating prolactin levels and risk of ovarian cancer is unknown. Methods: We conducted a nested case-control study of 230 cases and 432 individually matched controls within three prospective cohorts to evaluate whether pre-diagnostic circulating prolactin is associated with subsequent risk of ovarian cancer. We also assessed whether lifestyle and reproductive factors are associated with circulating prolactin among controls. Results: Prolactin levels were significantly lower among post- versus pre-menopausal women, parous versus nulliparous women, and past versus never users of oral contraceptives in our cross-sectional analysis of controls. In our nested case-control study, we observed a non-significant positive association between circulating prolactin and ovarian cancer risk (ORQ4vsQ1 1.56, 95 {\%} CI 0.94, 2.63, p trend 0.15). Our findings were similar in multivariate-adjusted models and in the subgroup of women who donated blood ≥5 years prior to diagnosis. We observed a significant positive association between prolactin and risk for the subgroup of women with BMI ≥25 kg/m2 (ORQ4vsQ1 3.10, 95 {\%} CI 1.39, 6.90), but not for women with BMI 2 (OR Q4vsQ1 0.81, 95 {\%} CI 0.40, 1.64). Conclusions: Our findings suggest that prolactin may be associated with increased risk of ovarian cancer, particularly in overweight/obese women. Factors associated with reduced risk of ovarian cancer, such as parity and use of oral contraceptives, were associated with lower prolactin levels, which suggests that modulation of prolactin may be a mechanism underlying their association with risk.",
keywords = "Ovarian cancer, Plasma, Prolactin, Serum",
author = "Clendenen, {Tess V.} and Arslan, {Alan A.} and Lokshin, {Anna E.} and Mengling Liu and Eva Lundin and Koenig, {Karen L.} and Franco Berrino and Goran Hallmans and Annika Idahl and Vittorio Krogh and Annekatrin Lukanova and Adele Marrangoni and Paola Muti and Nolen, {Brian M.} and Nina Ohlson and Shore, {Roy E.} and Sabina Sieri and Anne Zeleniuch-Jacquotte",
year = "2013",
month = "4",
doi = "10.1007/s10552-013-0156-6",
language = "English",
volume = "24",
pages = "741--748",
journal = "Cancer Causes and Control",
issn = "0957-5243",
publisher = "Springer International Publishing AG",
number = "4",

}

TY - JOUR

T1 - Circulating prolactin levels and risk of epithelial ovarian cancer

AU - Clendenen, Tess V.

AU - Arslan, Alan A.

AU - Lokshin, Anna E.

AU - Liu, Mengling

AU - Lundin, Eva

AU - Koenig, Karen L.

AU - Berrino, Franco

AU - Hallmans, Goran

AU - Idahl, Annika

AU - Krogh, Vittorio

AU - Lukanova, Annekatrin

AU - Marrangoni, Adele

AU - Muti, Paola

AU - Nolen, Brian M.

AU - Ohlson, Nina

AU - Shore, Roy E.

AU - Sieri, Sabina

AU - Zeleniuch-Jacquotte, Anne

PY - 2013/4

Y1 - 2013/4

N2 - Purpose: Indirect evidence from experimental and epidemiological studies suggests that prolactin may be involved in ovarian cancer development. However, the relationship between circulating prolactin levels and risk of ovarian cancer is unknown. Methods: We conducted a nested case-control study of 230 cases and 432 individually matched controls within three prospective cohorts to evaluate whether pre-diagnostic circulating prolactin is associated with subsequent risk of ovarian cancer. We also assessed whether lifestyle and reproductive factors are associated with circulating prolactin among controls. Results: Prolactin levels were significantly lower among post- versus pre-menopausal women, parous versus nulliparous women, and past versus never users of oral contraceptives in our cross-sectional analysis of controls. In our nested case-control study, we observed a non-significant positive association between circulating prolactin and ovarian cancer risk (ORQ4vsQ1 1.56, 95 % CI 0.94, 2.63, p trend 0.15). Our findings were similar in multivariate-adjusted models and in the subgroup of women who donated blood ≥5 years prior to diagnosis. We observed a significant positive association between prolactin and risk for the subgroup of women with BMI ≥25 kg/m2 (ORQ4vsQ1 3.10, 95 % CI 1.39, 6.90), but not for women with BMI 2 (OR Q4vsQ1 0.81, 95 % CI 0.40, 1.64). Conclusions: Our findings suggest that prolactin may be associated with increased risk of ovarian cancer, particularly in overweight/obese women. Factors associated with reduced risk of ovarian cancer, such as parity and use of oral contraceptives, were associated with lower prolactin levels, which suggests that modulation of prolactin may be a mechanism underlying their association with risk.

AB - Purpose: Indirect evidence from experimental and epidemiological studies suggests that prolactin may be involved in ovarian cancer development. However, the relationship between circulating prolactin levels and risk of ovarian cancer is unknown. Methods: We conducted a nested case-control study of 230 cases and 432 individually matched controls within three prospective cohorts to evaluate whether pre-diagnostic circulating prolactin is associated with subsequent risk of ovarian cancer. We also assessed whether lifestyle and reproductive factors are associated with circulating prolactin among controls. Results: Prolactin levels were significantly lower among post- versus pre-menopausal women, parous versus nulliparous women, and past versus never users of oral contraceptives in our cross-sectional analysis of controls. In our nested case-control study, we observed a non-significant positive association between circulating prolactin and ovarian cancer risk (ORQ4vsQ1 1.56, 95 % CI 0.94, 2.63, p trend 0.15). Our findings were similar in multivariate-adjusted models and in the subgroup of women who donated blood ≥5 years prior to diagnosis. We observed a significant positive association between prolactin and risk for the subgroup of women with BMI ≥25 kg/m2 (ORQ4vsQ1 3.10, 95 % CI 1.39, 6.90), but not for women with BMI 2 (OR Q4vsQ1 0.81, 95 % CI 0.40, 1.64). Conclusions: Our findings suggest that prolactin may be associated with increased risk of ovarian cancer, particularly in overweight/obese women. Factors associated with reduced risk of ovarian cancer, such as parity and use of oral contraceptives, were associated with lower prolactin levels, which suggests that modulation of prolactin may be a mechanism underlying their association with risk.

KW - Ovarian cancer

KW - Plasma

KW - Prolactin

KW - Serum

UR - http://www.scopus.com/inward/record.url?scp=84876491383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876491383&partnerID=8YFLogxK

U2 - 10.1007/s10552-013-0156-6

DO - 10.1007/s10552-013-0156-6

M3 - Article

VL - 24

SP - 741

EP - 748

JO - Cancer Causes and Control

JF - Cancer Causes and Control

SN - 0957-5243

IS - 4

ER -